9 February 2021
Hogan Lovells assists EyePoint Pharmaceuticals on transformative follow-on public offering of common stock
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Steve Abrams Lead | Hogan Lovells Cadwalader | Partner | Not stated | Philadelphia |
| Stephen Nicolai | Hogan Lovells Cadwalader | Counsel | Not stated | Not stated |
| Susan Lee | Hogan Lovells Cadwalader | Partner | Not stated | Washington, D.C. |
| Bob Underwood | Hogan Lovells Cadwalader | Partner | Not stated | Boston |
| Teresa Lavenue | Hogan Lovells Cadwalader | Counsel | Not stated | Washington, D.C. |
| Gibby Wagner | Hogan Lovells Cadwalader | Associate | Not stated | Philadelphia |
| Sally Gu | Hogan Lovells Cadwalader | Associate | Not stated | Washington, D.C. |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 115m (US$115 million)
- What the figure measures
- Issue size
- Client
- EyePoint Pharmaceuticals, Inc.Issuer
- Counterparties
- Cowen (Underwriters)
Guggenheim Securities (Underwriters)